Janssen submits applications seeking approval of Stelara® in U.S. and EU
Janssen Biotech and Janssen-Cilag announced submission of a BLA to the FDA and a Grouped Type II Variation/Extension Application to the EMA seeking approval of STELARA® (ustekinumab) for treatment of adult patients with moderately to severely active Crohn's disease. November 30, 2015